Another recent preclinical study demonstrated synergistic effects of menin-MLL inhibition in combination with various inhibitors of the tyrosine kinase receptor FLT3, including the FDA-approved AML therapies quizartinib and gilteritinib, in AML cells with FLT3 mutations (found in 10% of MLL1r and 60% of NPM1c AML patients) (60). The gene discussed is FLT3; the disease is acute myeloid leukemia.